Cipla Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Achin Gupta

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Achin Gupta (49 yo)

no data

Görev süresi

Mr. Achin Gupta serves as Managing Director, Global Chief Executive Officer and Additional Director of Cipla Limited since April 01, 2026. He served as Chief Executive Officer of One India Business at Cipl...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Achin Gupta	MD, Global CEO & Additional Director	no data	Veri yok	Veri yok
Pradeep Bhadauria	President & Global Chief Scientific Officer	6.1yrs	Veri yok	Veri yok
Ashish Adukia	Global Chief Financial Officer	3.7yrs	Veri yok	Veri yok
Dinesh Jain	Senior VP & Head of Corporate Finance	no data	Veri yok	Veri yok
Sneha Hiranandani	Chief Information Officer	1.8yrs	Veri yok	Veri yok
Diksha Maheshwari	Head of Investor Relations	no data	Veri yok	Veri yok
Rajendra Chopra	Compliance Officer & Company Secretary	9.2yrs	₹15.30m	Veri yok
Meera Vanjari	Global General Counsel	no data	Veri yok	Veri yok
Heena Kanal	Senior Vice-President of Corporate Communications	no data	Veri yok	Veri yok
Arun Kakatkar	Global Chief People Officer	less than a year	Veri yok	Veri yok
Jaideep Gogtay	Global Chief Medical Officer	1.8yrs	Veri yok	Veri yok
Anurag Mishra	Head of Cipla Foundation	no data	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: CIPLA 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Achin Gupta	MD, Global CEO & Additional Director	no data	Veri yok	Veri yok
Yusuf Hamied	Non-Executive Chairman	53.8yrs	₹25.70m	18.63% $ 2.0b
Adil Zainulbhai	Non Executive Director	11.8yrs	₹21.90m	Veri yok
Kamil Hamied	Non-Executive Director	1.4yrs	₹10.70m	1.35% $ 144.7m
Robert Stewart	Independent Director	4.9yrs	₹15.10m	Veri yok
Sharmila Paranjpe	Independent Director	1.6yrs	₹5.60m	Veri yok
Maya Hari	Independent Director	1.4yrs	₹4.40m	Veri yok
Mandar Vaidya	Independent Director	3.8yrs	₹9.00m	Veri yok
Prathivadibhayankara Ramesh	Independent Vice-Chairman	4.8yrs	₹10.30m	Veri yok
Balram Bhargava	Independent Director	2yrs	₹8.90m	Veri yok
Abhijit Joshi	Non-Executive Non Independent Director	1.6yrs	₹15.00m	Veri yok

2.0yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CIPLA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/16 14:52
Gün Sonu Hisse Fiyatı	2026/04/16 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cipla Limited 63 Bu analistlerden 35, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Prashant Nair	Ambit Capital
Nitin Bhasin	Ambit Capital
Ashwin Mehta	Ambit Capital

Cipla Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Cipla Appoints Achin Gupta as Global Chief Executive Officer, Effective 1 April 2026

Cipla Ltd Announces Resignation of Umang Vohra as Chief Executive Officer, Effective March 31, 2026

Cipla Limited, Annual General Meeting, Jul 16, 2025

Cipla Limited Approves the Elevation of Achin Gupta as Global Chief Operating Officer, Effective 1 February 2025

Cipla Limited Announces Resignation of Rajeev Kumar Sinha as Global Chief Manufacturing Officer, Effective April 2, 2025

Cipla Limited Announces Executive Appointments

Recent updates

Cipla Limited to Report Q4, 2026 Results on May 13, 2026

Fennec Pharmaceuticals Inc. Settles Patent Litigation with Cipla Limited and Cipla Usa, Inc. Regarding Pedmark

Cipla Appoints Achin Gupta as Global Chief Executive Officer, Effective 1 April 2026

Cipla Limited to Report Q3, 2026 Results on Jan 23, 2026

Cipla Ltd Announces Resignation of Umang Vohra as Chief Executive Officer, Effective March 31, 2026

Cipla Limited to Report Q2, 2026 Results on Oct 30, 2025

Cipla Limited to Report Q1, 2026 Results on Jul 25, 2025

Cipla Limited Recommends Special Dividend for the financial year ended March 31, 2025

Cipla Limited announces Annual dividend, payable on August 15, 2025

Cipla Limited, Annual General Meeting, Jul 16, 2025

Cipla Limited to Report Q4, 2025 Results on May 13, 2025

Cipla Limited Receives Final Approval from United States Food and Drug Administration for New Drug Application Submit for Nilotinib Capsules 50, 150 and 200 Mg

Cipla Limited Approves the Elevation of Achin Gupta as Global Chief Operating Officer, Effective 1 February 2025

Cipla Limited Announces Resignation of Rajeev Kumar Sinha as Global Chief Manufacturing Officer, Effective April 2, 2025

Cipla Limited to Report Q3, 2025 Results on Jan 28, 2025

Cipla Promoters Reportedly May Sell 1.72% Stake Worth INR 20,000 Million via Block Deal

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Cipla Limited Announces Executive Appointments

Cipla Limited to Report Q2, 2025 Results on Oct 29, 2024

Cipla Limited Announces Resignation of M K Hamied as Vice Chairman and Non-Executive Director, Effective October 29, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan, Non-Executive Director

Cipla Limited to Report Q1, 2025 Results on Jul 26, 2024

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Cipla Limited, Annual General Meeting, Aug 20, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla Limited Announces Partnership with the Premier Medical Corporation Private Limited for Commercialisation of the Rapid Antigen Test Kits for COVID-19 in India

Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID (Lenalidomide) with Cipla

Cipla Limited Launches Covi-G for COVID-19 Rapid Antibody Detection

Cipla Limited Receives Final Approval for Generic Version of Biogen Idec Inc.'S Tecfidera® (Dimethyl Fumarate Dr Capsules 120Mg, 240Mg and 120Mg/240Mg Starter Pack)

Cipla Limited Receives Final Approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Dimethyl Fumarate DR Capsules Starter Pak

Cipla Limited Launches Generic Version of Broad-Spectrum Anti-Viral Drug Remdesivir (Branded Cipremi), to Be Used on Critically Ill Covid Patients in the Hospitals

Cipla Limited to Report Q3, 2021 Results on Feb 05, 2021

Cipla Limited to Report Q1, 2021 Results on Aug 07, 2020

CEO